Opko Health Inc (OPK) has risen sharply, recording gains of 1.11% in the past 4 weeks. However, the stock has corrected -0.49% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 0.07% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 0.8% and the 50-Day Moving Average is 3.29%. Opko Health Inc (NYSE:OPK): stock turned positive on Friday. Though the stock opened at $10.05, the bulls momentum made the stock top out at $10.06 level for the day. The stock recorded a low of $9.97 and closed the trading day at $10.06, in the green by 0.10%. The total traded volume for the day was 1,451,533. The stock had closed at $10.05 in the previous days trading.
The company Insiders own 40.74% of Opko Health Inc shares according to the proxy statements. Institutional Investors own 19.97% of Opko Health Inc shares. During last six month period, the net percent change held by insiders has seen a change of -0.09%. Also, Major Brokerage house, Deutsche Bank maintains its ratings on Opko Health Inc (NYSE:OPK). In the latest research report, Deutsche Bank lowers the target price from $11 per share to $10 per share. According to the latest information available, the shares are now rated Hold by the analysts at the agency. The rating by the firm was issued on June 16, 2016.
OPKO Health, Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile, Spain, Mexico, Israel, Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.